This completed clinical trial evaluated SNK01, a personalized natural killer cell therapy, in 27 patients with advanced cancers that had failed multiple treatments. Natural killer cells are immune cells that can identify and destroy cancer cells. The study tested SNK01 alone and combined with immunotherapy drugs avelumab or pembrolizumab. Researchers focused on safety and preliminary effectiveness in patients whose cancers had progressed despite three or more previous treatment attempts. This approach represents personalized immunotherapy using the patient's own enhanced immune cells to fight cancer.
